rbs valutaion $3.19, page-2

finally ACR is green, good for a change.

Where on earth is all the news that is due??? FDA re Elanco product is now well overdue, details of any windfall resulting from VIVUS breach ($1m anyone?), details of plans re Evamist etc etc.

Any case the sub $1.90 dip was a good buying op. Only problem is now we have to cycle through the good selling op post $2. Say the average buy lately has been $1.90 I think $2.10 will now be a hurdle.

But surely by the end of the year we have to be close to $3, if you're not in by the time Axiron is confirmed (if it is!) you won't get a bite of that $200m.

We should see a slow and steady leap frog effect with bottom feeders/rampers cycling the stock, skimming %10 at every opportunity and creating a headwind for ACR, but she's a tough one and will push on up to $3 by Feb '11.